Alvaro
Lassaletta Atienza
Consultor Médico
University of Melbourne
Melbourne, AustraliaPublikationen in Zusammenarbeit mit Forschern von University of Melbourne (7)
2023
-
Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908
Neuro-Oncology, Vol. 25, Núm. 8, pp. 1530-1545
-
Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation Sparing Approaches: An International Cohort Study
Journal of Clinical Oncology, Vol. 41, Núm. 10, pp. 1921-1932
2021
-
Clinical phenotypes and prognostic features of embryonal tumours with multi-layered rosettes: a Rare Brain Tumor Registry study
The Lancet Child and Adolescent Health, Vol. 5, Núm. 11, pp. 800-813
-
Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study
The Lancet Oncology, Vol. 22, Núm. 10, pp. 1416-1426
2019
-
A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor
Cancer Cell, Vol. 36, Núm. 1, pp. 51-67.e7
-
Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas
Nature Communications, Vol. 10, Núm. 1
-
Outcomes of BRAF V600E pediatric gliomas treated with targeted BRAF inhibition
JCO Precision Oncology